Treatment of Neurodegeneration with Brain Iron Accumulation (NBIA)

1. Symptomatic / Supportive Treatment

Dystonia

• Oral medications: Trihexyphenidyl (anticholinergic), baclofen, clonazepam, tetrabenazine
• Botulinum toxin injections: For focal dystonia
• Intrathecal baclofen pump: For severe generalized dystonia

Parkinsonism

• Levodopa/carbidopa: Often tried but response is variable and may be limited in PKAN
• Dopamine agonists: May provide partial benefit

Spasticity

• Baclofen (oral or intrathecal), tizanidine, physical therapy

Neuropsychiatric symptoms

• Antipsychotics, SSRIs, or mood stabilizers as clinically indicated

Seizures

• Standard antiepileptic drugs (e.g., valproate, levetiracetam) based on seizure type

2. Surgical Treatment

Deep Brain Stimulation (DBS)

• Globus pallidus internus (GPi) DBS is the most widely used surgical intervention for NBIA
• Has shown the most benefit for dystonia, particularly in PKAN patients
• Does not halt disease progression but can significantly improve quality of life and functional ability
• Response is variable; best results tend to be in patients with predominantly dystonic phenotype

3. Iron Chelation Therapy

• Deferiprone (an iron chelator that crosses the blood-brain barrier) has been studied in PKAN
• The TIRCON trial (Treat Iron-Related Childhood-Onset Neurodegeneration) evaluated deferiprone in PKAN — it reduced iron in the globus pallidus on MRI, but did not show significant clinical benefit on motor outcomes at 18 months
• Despite limited trial evidence, deferiprone is still used in some centers given its iron-reducing effect and acceptable safety profile
• Other chelators (deferoxamine, deferasirox) have less evidence for CNS iron removal

4. Substrate/Pathway-Specific Approaches

Pantethine (in PKAN)

• PANK2 mutations impair coenzyme A (CoA) biosynthesis; pantethine, a CoA precursor, has been studied as a potential bypass strategy
• Showed improvement in Drosophila models; human trials ongoing

CoA supplementation / fosmetpantotenate (RE-024)

• A phosphopantothenate replacement therapy designed to bypass the defective PANK2 enzyme
• Phase 3 trial (FORT trial) did not meet its primary endpoint, though some benefit was seen in subgroups
• Research is ongoing

5. Rehabilitative and Allied Health Support

• Physical therapy: To maintain mobility, prevent contractures
• Occupational therapy: Adaptive strategies for activities of daily living
• Speech and language therapy: For dysarthria and dysphagia
• Nutritional support / PEG tube feeding: In advanced disease with dysphagia
• Ophthalmology follow-up: Retinal degeneration monitoring (common in several NBIA subtypes)
• Psychosocial support for patients and families

Summary Table